source
- STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatmentProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
- GSK launches $2.5 billion restructuring plan to fund late-stage pipeline and offset upcoming HIV drug patent lossGSK reported $2.4 billion in impairment charges for the second quarter and unveiled a three‑year restructuring designed to save roughly $2.5 billion. The company says the savings will be redirecte…